|
1
|
Davies L, Morris LG, Haymart M, Chen AY,
Goldenberg D, Morris J, Ogilvie JB, Terris DJ, Netterville J, Wong
RJ, et al: American association of clinical endocrinologists and
American college of endocrinology disease state clinical review:
The increasing incidence of thyroid cancer. Endocr Pract.
21:686–696. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng H, Wang M, Jiang L, Chu H, Hu J,
Ning J, Li B, Wang D and Xu J: BRAF-activated long noncoding RNA
modulates papillary thyroid carcinoma cell proliferation through
regulating thyroid stimulating hormone receptor. Cancer Res Treat.
48:698–707. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneider AB and Sarne DH: Long-term risks
for thyroid cancer and other neoplasms after exposure to radiation.
Nat Clin Pract Endocrinol Metab. 1:82–91. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cho BY, Choi HS, Park YJ, Lim JA, Ahn HY,
Lee EK, Kim KW, Yi KH, Chung JK, Youn YK, et al: Changes in the
clinicopathological characteristics and outcomes of thyroid cancer
in Korea over the past four decades. Thyroid. 23:797–804. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geraldo MV, Fuziwara CS, Friguglieti CU,
Costa RB, Kulcsar MA, Yamashita AS and Kimura ET: MicroRNAs
miR-146-5p and let-7f as prognostic tools for aggressive papillary
thyroid carcinoma: A case report. Arq Bras Endocrinol Metabol.
56:552–557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vasko VV and Saji M: Molecular mechanisms
involved in differentiated thyroid cancer invasion and metastasis.
Curr Opin Oncol. 19:11–17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Q, Ji M, Guan H, Shi B and Hou P:
Shikonin inhibits thyroid cancer cell growth and invasiveness
through targeting major signaling pathways. J Clin Endocrinol
Metab. 98:E1909–E1917. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambros V: microRNAs: Tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Srivastava A, Goldberger H, Dimtchev A,
Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen
LN, et al: MicroRNA profiling in prostate cancer-the diagnostic
potential of urinary miR-205 and miR-214. PLoS One. 8:e769942013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hodge LS, Elsawa SF, Grote DM,
Price-Troska TL, Asmann YW, Fonseca R, Gertz MA, Witzig TE, Novak
AJ and Ansell SM: MicroRNA expression in tumor cells from
Waldenstrom's macroglobulinemia reflects both their normal and
malignant cell counterparts. Blood Cancer J. 1:e242011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shah NR and Chen H: MicroRNAs in
pathogenesis of breast cancer: Implications in diagnosis and
treatment. World J Clin Oncol. 5:48–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fernandez S, Risolino M, Mandia N, Talotta
F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P:
miR-340 inhibits tumor cell proliferation and induces apoptosis by
targeting multiple negative regulators of p27 in non-small cell
lung cancer. Oncogene. 34:3240–3250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY,
Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, et al: MicroRNA-30b functions
as a tumour suppressor in human colorectal cancer by targeting
KRAS, PIK3CD and BCL2. J Pathol. 232:415–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen W, Wang J, Liu S, Wang S, Cheng Y,
Zhou W, Duan C and Zhang C: MicroRNA-361-3p suppresses tumor cell
proliferation and metastasis by directly targeting SH2B1 in NSCLC.
J Exp Clin Cancer Res. 35:762016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lima CR, Geraldo MV, Fuziwara CS, Kimura
ET and Santos MF: MiRNA-146b-5p upregulates migration and invasion
of different papillary thyroid carcinoma cells. BMC Cancer.
16:1082016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Srivastava SK, Bhardwaj A, Singh S, Arora
S, Wang B, Grizzle WE and Singh AP: MicroRNA-150 directly targets
MUC4 and suppresses growth and malignant behavior of pancreatic
cancer cells. Carcinogenesis. 32:1832–1839. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li X, Chen L, Wang W, Meng FB, Zhao RT and
Chen Y: MicroRNA-150 inhibits cell invasion and migration and is
downregulated in human osteosarcoma. Cytogenet Genome Res.
146:124–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yokobori T, Suzuki S, Tanaka N, Inose T,
Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H and Kuwano
H: MiR-150 is associated with poor prognosis in esophageal squamous
cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci.
104:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pizzini S, Bisognin A, Mandruzzato S,
Biasiolo M, Facciolli A, Perilli L, Rossi E, Esposito G, Rugge M,
Pilati P, et al: Impact of microRNAs on regulatory networks and
pathways in human colorectal carcinogenesis and development of
metastasis. BMC Genomics. 14:5892013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu F, Lu Z, Chen B, Dong P and Zheng J:
microRNA-150: A promising novel biomarker for hepatitis B
virus-related hepatocellular carcinoma. Diagn Pathol. 10:1292015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun W, Zhang Z, Wang J, Shang R, Zhou L,
Wang X, Duan J, Ruan B, Gao Y, Dai B, et al: MicroRNA-150
suppresses cell proliferation and metastasis in hepatocellular
carcinoma by inhibiting the GAB1-ERK axis. Oncotarget.
7:11595–11608. 2016.PubMed/NCBI
|
|
26
|
Jin M, Yang Z, Ye W, Xu H and Hua X:
MicroRNA-150 predicts a favorable prognosis in patients with
epithelial ovarian cancer, and inhibits cell invasion and
metastasis by suppressing transcriptional repressor ZEB1. PLoS One.
9:e1039652014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Watanabe A, Tagawa H, Yamashita J, Teshima
K, Nara M, Iwamoto K, Kume M, Kameoka Y, Takahashi N, Nakagawa T,
et al: The role of microRNA-150 as a tumor suppressor in malignant
lymphoma. Leukemia. 25:1324–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dezhong L, Xiaoyi Z, Xianlian L, Hongyan
Z, Guohua Z, Bo S, Shenglei Z and Lian Z: miR-150 is a factor of
survival in prostate cancer patients. J BUON. 20:173–179.
2015.PubMed/NCBI
|
|
29
|
Li J, Hu L, Tian C, Lu F, Wu J and Liu L:
microRNA-150 promotes cervical cancer cell growth and survival by
targeting FOXO4. BMC Mol Biol. 16:242015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gu XY, Wang J, Luo YZ, Du Q, Li RR, Shi H
and Yu TP: Down-regulation of miR-150 induces cell proliferation
inhibition and apoptosis in non-small-cell lung cancer by targeting
BAK1 in vitro. Tumour Biol. 35:5287–5293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang S, Chen Y, Wu W, Ouyang N, Chen J,
Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast
cancer growth and malignant behavior by targeting the pro-apoptotic
purinergic P2×7 receptor. PLoS One. 8:e807072013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K,
Ren G, Su T, Pan Y, Feng B, et al: MiR-150 promotes gastric cancer
proliferation by negatively regulating the pro-apoptotic gene EGR2.
Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yin QW, Sun XF, Yang GT, Li XB, Wu MS and
Zhao J: Increased expression of microRNA-150 is associated with
poor prognosis in non-small cell lung cancer. Int J Clin Exp
Pathol. 8:842–846. 2015.PubMed/NCBI
|
|
34
|
Ito M, Teshima K, Ikeda S, Kitadate A,
Watanabe A, Nara M, Yamashita J, Ohshima K, Sawada K and Tagawa H:
MicroRNA-150 inhibits tumor invasion and metastasis by targeting
the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma.
Blood. 123:1499–1511. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feng J, Yang Y, Zhang P, Wang F, Ma Y, Qin
H and Wang Y: miR-150 functions as a tumour suppressor in human
colorectal cancer by targeting c-Myb. J Cell Mol Med. 18:2125–2134.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang WH, Chen J, Zhao F, Zhang BR, Yu HS,
Jin HY and Dai JH: MiR-150-5p suppresses colorectal cancer cell
migration and invasion through targeting MUC4. Asian Pac J Cancer
Prev. 15:6269–6273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lock FE, Ryan KR, Poulter NS, Parsons M
and Hotchin NA: Differential regulation of adhesion complex
turnover by ROCK1 and ROCK2. PLoS One. 7:e314232012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou X, Wei M and Wang W: MicroRNA-340
suppresses osteosarcoma tumor growth and metastasis by directly
targeting ROCK1. Biochem Biophys Res Commun. 437:653–658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oellers P, Schroer U, Senner V, Paulus W
and Thanos S: ROCKs are expressed in brain tumors and are required
for glioma-cell migration on myelinated axons. Glia. 57:499–509.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lochhead PA, Wickman G, Mezna M and Olson
MF: Activating ROCK1 somatic mutations in human cancer. Oncogene.
29:2591–2598. 2010. View Article : Google Scholar : PubMed/NCBI
|
